Neoadjuvant mFOLFIRINOX Provides OS Benefit in Borderline Resectable Pancreatic Cancer

home / oncclub / neoadjuvant-mfolfirinox-provides-os-benefit-in-borderline-resectable-pancreatic-cancer

Matthew H. G. Katz, MD, sheds light on the phase 2 A021501 trial (NCT02839343), which showed that neoadjuvant mFOLFIRINOX provided a favorable overall survival benefit in patients with borderline resectable pancreatic ductal adenocarcinoma when administered prior to pancreatectomy.